Probenecid-boosted dosing offers a stability-compliant route to intravenous amoxicillin for community antibiotic therapy

A pharmacokinetic study backed by the British Society for Antimicrobial Chemotherapy’s OPAT Initiative examined how to deliver intravenous amoxicillin for outpatient parenteral antimicrobial therapy (OPAT) Primary Study. Citrate buffering, one approach to enabling continuous infusion, failed the stability criteria set out in the UK’s Yellow Cover Document reference standard for OPAT antibiotic stability. Probenecid-boosted intermittent or extended-infusion regimens, by contrast, achieved at least 90% target attainment against minimum inhibitory concentrations of up to 8–16 mg/L.

This study was conducted against the established UK stability reference standard for OPAT formulations, and its authorship includes named specialists from the national OPAT Initiative, giving it direct relevance to UK community antibiotic delivery practice specifically, rather than requiring extrapolation from an international dataset.

For services with a stability-limited antibiotic formulary, this offers a practical route to broaden the intravenous antibiotics available for community delivery without depending solely on lipoglycopeptides, using a probenecid-boosted regimen rather than continuous citrate-buffered infusion.